However, a potent inhibitor of the p38 MAPK (losmapimod) have minimal effects on lung function or sputum neutrophils in patients with COPD (Lomas et al., 2012), no clinical studies with inhibitors of the JNK and ERK1/2 have been accomplished in COPD. The gene discussed is MAPK8; the disease is chronic obstructive pulmonary disease.